A Case of Pseudo-progression-like Pleurisy After Combined Treatment with Nivolumab and Ipilimumab for Lung Adenocarcinoma-Reference-Cited by-同舟云学术

A Case of Pseudo-progression-like Pleurisy After Combined Treatment with Nivolumab and Ipilimumab for Lung Adenocarcinoma

Published:2022-10-20 Issue:5 Volume:62 Page:400-405
ISSN:0386-9628
Container-title:Haigan
language:en
Short-container-title:JJLC

Author:

Terashima Yuto¹,Hisakane Kakeru¹,Atsumi Kenichiro¹,Terashi Naoki¹,Suzuki Ayana¹,Nagata Koji²,Seike Masahiro³,Gemma Akihiko³,Hirose Takashi¹

Affiliation:

1. Department of Pulmonary Medicine and Medical Oncology, Nippon Medical School Tamanagayama Hospital

2. Department of Pathology, Nippon Medical School Tamanagayama Hospital

3. Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School

Publisher

Japan Lung Cancer Society

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.jstage.jst.go.jp/article/haigan/62/5/62_400/_pdf

Reference12 articles.

1. 1. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019; 381: 2020-2031.

2. 2. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22: 198-211.

3. 3. Jia W, Gao Q, Han A, Zhu H, Yu J. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019; 16: 655-670.

4. 4. Li H, Zhou X, Zhang D, Wang G, Cheng X, Xu C, et al. Early onset immune-related adverse event to identify pseudo-progression in a patient with ovarian cancer treated with nivolumab: a case report and review of the literature. Front Med. 2020; 7: 366-371.

5. 5. Yhim HY, Jeon SY, Lee CH, Lee NR. Bilateral pleural effusion associated with atezolizumab in a patient with Lynch syndrome-related urothelial carcinoma: a case report. Ann Palliat Med. 2021; 21: 1148-1155.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case of Pleurisy as Immune-related Adverse Events of Neoadjuvant Nivolumab and Chemotherapy After Lobectomy;Haigan;2024-08-20

2. Ipilimumab/nivolumab;Reactions Weekly;2023-04-22